共 50 条
Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics
被引:17
作者:
Pang, Kuin Tian
[1
,5
]
Yang, Yuan Sheng
[1
]
Zhang, Wei
[1
]
Ho, Ying Swan
[1
]
Sormanni, Pietro
[2
]
Michaels, Thomas C. T.
[3
,4
]
Walsh, Ian
[1
]
Chia, Sean
[1
]
机构:
[1] ASTAR, Bioproc Technol Inst, Singapore, Singapore
[2] Univ Cambridge, Yusuf Hamied Dept Chem, Chem Hlth, Cambridge, England
[3] Swiss Fed Inst Technol, Inst Biochem, Dept Biol, Otto Stern Weg 3, CH-8093 Zurich, Switzerland
[4] Swiss Fed Inst Technol, Bringing Mat Life Initiat, Zurich, Switzerland
[5] Nanyang Technol Univ, Sch Chem Chem Engn & Biotechnol, Singapore, Singapore
基金:
英国医学研究理事会;
关键词:
Antibodies;
Protein aggregation;
Protein self-association;
Developability;
Chemical kinetics;
MONOCLONAL-ANTIBODY AGGREGATION;
NUCLEATED-POLYMERIZATION MODEL;
COMPETING GROWTH;
CONFORMATIONAL STABILITY;
DRIVING FORCES;
SINGLE-DOMAIN;
IGG1;
ANTIBODY;
HIGH-PRESSURE;
LOW PH;
KINETICS;
D O I:
10.1016/j.biotechadv.2023.108192
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
In antibody development and manufacturing, protein aggregation is a common challenge that can lead to serious efficacy and safety issues. To mitigate this problem, it is important to investigate its molecular origins. This review discusses (1) our current molecular understanding and theoretical models of antibody aggregation, (2) how various stress conditions related to antibody upstream and downstream bioprocesses can trigger aggregation, and (3) current mitigation strategies employed towards inhibiting aggregation. We discuss the relevance of the aggregation phenomenon in the context of novel antibody modalities and highlight how in silico approaches can be exploited to mitigate it.
引用
收藏
页数:14
相关论文
共 50 条